Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Withdrawn 2Completed 2Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Uterine Cervical Neoplasms 5Prostatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Pancreatic Neoplasms 1Melanoma 1Hemangiosarcoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 182Radiotherapy 81Paclitaxel 80Brachytherapy 74Carboplatin 72pembrolizumab 63Bevacizumab 40Surveys and Questionnaires 29Colposcopy 29Radiation 28Gemcitabine 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 27Topotecan 26Magnetic Resonance Spectroscopy 24Blood Specimen Collection 23human papillomavirus vaccine, L1 type 16, 18 22Nivolumab 22Drug Therapy 22Papillomavirus Vaccines 20atezolizumab 19Platinum 19Radiotherapy, Intensity-Modulated 18Biopsy 18Docetaxel 17Taxes 16Cyclophosphamide 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × balstilimab × Gynecologic × Clear all
NCT03894215 2026-03-27

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Agenus Inc.

Phase 2 Terminated
211 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Agenus Inc.

Phase 1/2 Completed
211 enrolled 29 charts
Gynecologic

Uterine Cervical Neoplasms

NCT05033132 2024-03-28

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Agenus Inc.

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT03495882 2023-07-05

Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Agenus Inc.

Phase 1/2 Completed
154 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡